Kinross Gold Corporation (NYSE: KGC) has obtained authorization from the Ecuadorian Ministry of Non-Renewable Natural Resources to re-commence advanced exploration activities at the Fruta del Norte (FDN) gold project in Zamora-Chinchipe province in Ecuador.
With this authorization, Kinross expects to re-commence its drilling program at FDN shortly. The program includes a 20,000 meter drilling campaign to support completion of a feasibility study. The Company plans to use four drills to execute the drilling campaign which is expected to take six months to complete. Kinross expects to complete a pre-feasibility study in January 2010.
"The re-launch of the advanced exploration program is an important and positive development for the FDN project and for the mining industry in Ecuador," said Tye Burt, President and CEO. "We look forward to working closely with the government of Ecuador and local communities to advance the development of responsible mining at FDN," he added.
[SM]
Sanofi-aventis (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.
Sanofi-aventis will increase its annual funding commitment from $100M to $160 million beginning in 2010, and the research funding will now extend through 2017. The companies aim to advance an average of four to five antibodies into clinical development each year. In addition to its VelocImmune(®) technology, Regeneron will contribute to the collaboration its next generation technologies related to antibody generation.
Sanofi-aventis has an option to extend the discovery program for up to an additional three years for further antibody development and preclinical activities. The amendments announced today do not change the financial terms of the November 2007 agreement governing the development and commercialization of antibody drug candidates arising from the discovery collaboration.
[SM]
Stryker Corporation (NYSE: SYK) has acquired OtisMed Corporation, a privately held, software technology firm. OtisMed will focus on customizable instrumentation that has the potential to complement the many benefits that surgeons and patients realize from Stryker's Triathlon Knee System, as well as other Stryker implants. OtisMed will operate as part of Stryker's Orthopaedics Division and remain located in Alameda, California.
In addition, Stryker announced it has entered into definitive agreements with Mutoh Co., Ltd., a Japanese company, and certain of its affiliates, and Synergetics USA, Inc. (Nasdaq: SURG) to acquire assets used to produce the Sonopet Ultrasonic Aspirator control consoles, hand pieces and accessories as well as the worldwide rights to market and sell these products. The closing of these combined transactions is anticipated to occur prior to December 31, 2009, subject to agreed upon conditions. These products will be incorporated into Stryker's Instruments Division which is headquartered in Kalamazoo, Michigan.
The terms of these two combined transactions include $67 million in upfront payments as well as potential future milestone and royalty payments of up to an additional $36 million.
[SM]
In a Form 8-K, Adobe Systems (Nasdaq: ADBE) announced a workforce reduction to appropriately align its costs in connection with its 2010 operating plan. As a result, Adobe expectx to eliminate approximately 680 full-time positions worldwide.
The company expects to record in the aggregate approximately $65.0-$71.0 million in pre-tax restructuring charges associated with this Restructuring Plan. Included in these charges are:
- approximately $17.0-$19.0 million primarily related to the consolidation of leased facilities and
- approximately $48.0-$52.0 million related to employee severance arrangements.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. Customers will begin receiving product on November 11, 2009.
Annual sales of Prevacid Delayed-Release Capsules were approximately $2.97 billion in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.
More Corporate News
View Older Stories-
Adobe (ADBE) to cut 680 full-time positions, sees a $65-$71M pre-tax charge
-
ManTech (MANT) awarded a $286.5 million contract from the U.S. Army
-
Starbucks' (SBUX) Schultz Says Via Exceeding Expectations, Company Done Closing Stores
-
Highlights From DIVX's Q3 Conference Call; Licensing Business Transitioning to New Growth Categories; Guides Above for Q4 EPS
-
Ambac (ABK) Slammed as 10-Q Warns of Possible Bankruptcy Protection
-
Globecomm Systems (GCOM) Awarded $17.7 Million Contract
-
Highlights From ERTS's Q2 Conference Call: Largest Quarter for Digital Direct Revenues in EA's History; Guides In-line
-
SkyWest (SKYW) Reports October 2009 Traffic for Skywest Airlines and Atlantic Southeast Airlines
-
Highlights From PCLN's Q3 Conference Call: Bookings Up 33% Year-Over-Year, Guides Above for Q4
-
Activision Blizzard's (ATVI) New "Call of Duty" Has Gamers Buzzing, But Stock Flat
-
Hovnanian Enterprises (HOV) Sees Tax Refund of $250-$275M
-
Windstream (WIN) Closes Acquisition of D&E Communications, Deal Valued at $333M
-
Northrop Grumman (NOC) Receives $58M Delivery Order for C-RAM Systems Integration
-
Kenexa (KNXA) Opens New Office in Buenos Aires, Argentina
-
Mad Catz Interactive (MCZ) Opens Office in Barcelona, Spain
-
Ericsson (ERIC) Selected as Exclusive Supplier to MTS Allstream for High Speed Network
-
Peregrine Pharma (PPHMD) Says Study of Phosphatidylserine-Targeting Antibody Doubles Survival Times in Animals with Aggressive Brain Cancer
-
Merit Medical Systems (MMSI) Receives U.S. FDA 510(K) Clearance for Merit Laureate Guide Wire
-
Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
-
NTELOS Holdings (NTLS) Announces Workforce Reductions; Estimates $1.5M Cash Severance
-
MAG Silver (MVG) Announces Strong Gold and Molybdenum Assay Results from Pozo Seco Discovery
-
Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
-
PCTEL (PCTI) Settles Intellectual Property Dispute with Wilder Networks
-
Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
-
CGI Group (GIB) Signs Three-Year Application Support Contract with Rio Tinto (RTP)
-
Clearwire (CLWR) Agrees to Raise $1.56B in New Investment Capital from Sprint, Comcast, Time Warner Cable, Intel
-
AVANIR Pharma (AVNR) Announces Results from Zenvia Phase III STAR Trial
-
Clearwire (CLWR) to raise $1.56B from group led by Sprint (S), Comcast (CMCSA)
-
American Technology Corp. (ATCO) Receives $1.6M Follow-On LRAD 500X Order
-
Gilat Satellite (GILT) Receives Multi-Million Dollar Contract for Turnkey Broadband Solutions in Asia
-
Denison Mines (DNN) Makes Production Decision on Arizona 1 Uranium Deposit
-
Life Technologies (LIFE) and University of Cambridge Announce Translational Research Collaboration
-
ImmunoGen (IMGN) to Make Several Poster Presentations as AACR-NCI-EORTC Conference
-
BofA's Ken Lewis Sees Crisis 'Abating', But Says Banking Has 'Some Way to Go' to Recover
-
Novavax (NVAX) Begins Phase IIa of Flu VLP Vaccine Candidate in Adults 60 and Over
-
Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
-
TASER Int. (TASR) Announces U.S. Army Ordered 2500 Taser X26 ECDs
-
Jacobs Engineering Group (JEC) Awarded Contract From Suncor Energy (SU)
-
Helicos BioSciences (HLCS) Announces Filing of 10-Q; Disengages in Sale of Company
-
Bristol-Myers Squibb (BMY) and Alder Biopharma Agree to Develop Rheumatoid Arthritis Treatment
-
Eagle Rock Energy (EROC) Receives Joint Letter Regarding NGP and Black Stons Partnership Proposals
-
Dynavax Technologies (DVAX) To Purchase Symphony Dynamo; Will Acquire $20M in Cash and Hep C and Cancer Rights
-
DUSA Pharma (DUSA) Encouraged By SCC Study to Explore Benefits of Levulan PDT
-
Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
-
Semiconductor Manufacturing (SMI) Enters Settlement Agreement on All Pending Lawsuits
-
S&P Announces Change to US Index: LL for UCBH
-
Electronic Arts (ERTS) Makes Major Job Cuts As Q2 Profits Lag (Update)
-
Kraft (KFT) to Ask Holders to Vote to Issue New Shares
-
Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
-
Highlights From DISH's Q3 Conference Call - Q&A Session
